

KING'S HEALTH PARTNERS JOINT BOARDS MEETING

MINUTES OF THE KING'S HEALTH PARTNERS JOINT BOARDS HELD ON WEDNESDAY 26TH JULY 2017 IN THE KHP MEETING ROOM, COUNTING HOUSE

PRESENT	Prof Ed Byrne Prof Sir Robert Lechler Sir Hugh Taylor Dr Ian Abbs (for Amanda Pritchard) Lord Kerslake Prof Julia Wendon (for Nick Moberly) Roger Paffard Dr Matthew Patrick Lord Butler Dr Pamela Kirby Prof Garret FitzGerald (via Skype)	President and Principal, KCL Executive Director, KHP Chair, GStT NHS FT Chief Medical Officer, GSTT Chair, KCH NHS FT Medical Director, KCH Chair, SLaM NHS FT Chief Executive, SLaM NHS FT Non-Executive Director, KHP Non-Executive Director, KHP Non-Executive Director, KHP
APOLOGIES	Amanda Pritchard Nick Moberly Rt Hon Stephen Dorrell	Chief Executive, GStT NHS FT Chief Executive, KCH NHS FT Non-Executive Director, KHP
IN ATTENDANCE	Jill Lockett Professor Mark Richardson Dr Jozef Jarosz Karen Larcombe Professor Sir Graham Thornicroft	KHP Director, Performance & Delivery Item 2 Item 2 Item 2 Item 3

1. Introductions and welcome

Apologies were noted from Stephen Dorrell, Amanda Pritchard and Nick Moberly. Ed Byrne welcomed Prof Julia Wendon and Dr Ian Abbs representing Nick Moberly and Amanda Pritchard respectively.

The minutes of the previous meetings were agreed as a true record.

2. KHP Neurosciences

Ed Byrne welcomed Prof Mark Richardson, Dr Jozef Jarosz and Karen Larcombe to the meeting. Professor Richardson presented the progress and current thinking in the KHP Neurosciences programme noting the significant collaborations and developments across the research pipeline, the early developments in the strategic direction of the emerging clinical academic network for SE London and Kent and the ongoing challenges with clinical capacity across the partners.

Pam Kirby asked about the priority and focus required to achieve a (top ten) internationally competitive position and it was agreed that this needed considerable work across the partnership. Currently the partners are ranked top 20 globally in Neurosciences and will need to focus basic science and research efforts to boost the research impact and education scores to meet the outcomes achieved in North America.

The partners achieve consistently high clinical outcomes scores compared to UK benchmarks. Garret FitzGerald highlighted the translational medicine opportunities in pain and analgesia, potentially connecting the Mind and Body agenda. It was noted that there is an appetite for a stronger integration of the local teams, towards a “One Team” approach and that more pace could be given to this given the opportunities for London in this area as a world city and leader in life sciences. The NHS commissioning models will need to develop to support the advance of a clinical academic network but that the already good work in spinal pathways showed potential for strengthening research and education collaborations. KHP’s role as a system leader will be important along with a number of local partnership opportunities. It was noted that work is underway in developing the estates masterplan across the partners and opportunities to further develop the neuro rehabilitation offer should be considered within the timeframe.

The Joint Boards were excited about the programme and progress already underway and confirmed their ongoing support and for the detailed work plan. It was agreed that the Institute nomenclature was unhelpful given the range of pre-existing institute offerings across the neurosciences system locally. It was agreed that the programme would be known as KHP Neurosciences going forward.

- ***Action: it was agreed that the team would develop their world class action plan and share with the Joint Boards for further review by Winter 2018***
- ***KCH, Neurosciences and SLaM colleagues to test the opportunities for enhancing the closer relationship for neuro rehabilitation provision***
- ***Medical Directors and the Neurosciences team to consider network and specialised commissioning development going forward, in light of the emerging life sciences strategy***

3. King’s Improvement Science (KIS) and CLAHRC South London Annual Report

Ed Byrne welcomed Prof Sir Graham Thornicroft to the meeting. Professor Thornicroft presented the report of both CLAHRC and KIS activities over the past year. The metrics and outputs particularly in relation to grant income and published papers was noted as was the significant progress in capacity building, particularly doctoral students. The Joint Boards congratulated Professor Thornicroft and his teams on their considerable efforts. It was agreed that the KHP Institutes programme needed to be more strongly connected to the implementation science agenda and that the leaders of the local Sustainability and Transformation Partnership should be briefed about the progress in the evaluation and implementation science processes on offer locally.

It was agreed there would need to be careful collaboration to ensure the maximum benefit is achieved through a future renewal process. Professor Thornicroft was encouraged to bring his CLAHRC renewal proposal back to the partners as soon as is helpful.

Action: CLAHRC team to share their draft renewal proposals with the KHP Joint Boards in 2018/19.

4. KHP Institutes Update

Jill Lockett presented the progress and thinking across the KHP Institutes programme, confirming that both the Cardiovascular and Haematology Strategic Outline Cases had received internal approval from the partner Boards. Work would begin from the Autumn on the external engagement processes. A draft tender had been completed to bring in external advice regarding the governance and permissions of one team working in the Institutes. The advice and options for the way forward are expected at the KHP CEOs’ Action Group in November 2017. Ian Abbs noted the work on system leadership across the south of London and Kent that needed to develop to underpin the establishment of the new networks. The journey towards Outline Business Case stage would need to be carefully calibrated in terms of internal resource and talent to ensure

the best outcomes possible. This would be particularly important in launching the One Team model in advance of any buildings coming on stream. It was agreed that the work on clinical interdependencies and new commercial relationships would play a crucial role in the future vision.

Action: Jill Lockett to share the progress in the business case development and One Team governance advice through the Autumn.

5. Director's Report

Robert Lechler presented his report highlighting the following:

Royal Brompton & Harefield NHS FT - All acknowledged the benefit of the productive clinical academic conversations underway with the Royal Brompton and Harefield NHS FT.

STP - The Boards talked about developments in the local STP and recent rankings received from NHS England. It was agreed to have this as a major agenda item at a future meeting.

Rankings – it was noted that KCL had achieved a ranking of 18th in the world for life sciences and medicine, and 5th in UK. 4th for Dental world-wide, Nursing 3rd and Pharmacy 7th.

MRC Dementia Institute – KHP has been awarded an MRC Dementia Institute Centre status with funding of £13m over the next 5 years.

- **Action: Jill Lockett to work with the STP team on a progress update for a future meeting of the KHP Joint Boards.**

6. Strengthening the Leadership Team

Robert Lechler and the Trust Medical Directors left the meeting. Ed Byrne discussed the opportunities to strengthen the KHP leadership team with the recruitment of a senior medical professional with significant NHS Board member and clinical strategy experience to work alongside Professor Lechler to advance the Institutes agenda. Jill Lockett agreed to share the revised role description and conduct a search through the early autumn.

- **Action: Jill Lockett to revise the documentation and develop the forward plan.**

7. AOB

None

8. Date of next meeting:

**KHP Joint Boards
Thursday 21st September 2017
KHP Meeting Room
Guy's Hospital**